-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ua4lF+kN1PENnJArCbVed90DdIHhlYN1QlHjDP5dRoL87HuLSTJbX5UwH9RP7Urk RVmwzBMgG5dZt68En/i9TQ== 0001144204-07-012463.txt : 20070313 0001144204-07-012463.hdr.sgml : 20070313 20070313163813 ACCESSION NUMBER: 0001144204-07-012463 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070313 DATE AS OF CHANGE: 20070313 GROUP MEMBERS: FELIX J. BAKER SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81275 FILM NUMBER: 07691010 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAKER FELIX CENTRAL INDEX KEY: 0001087940 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: TISCH FAMILY INTERESTS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212420 MAIL ADDRESS: STREET 1: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 SC 13D/A 1 v068327_sc13da.htm Unassociated Document
Draft of August 15, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13D
Under the Securities Exchange Act of 1934
 
(Amendment No. 1)
 
Genomic Health, Inc
(Name of Issuer)
     
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
     
 
37244C101
  
 
(CUSIP Number)
  
     
Leo Kirby
667 Madison Avenue, 17th Floor
New York, NY 10021
(212) 339-5633
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
 
March 9, 2007
  
 
(Date of Event which Requires Filing of this Statement)
  
     

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. o
 
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

 

Page 1 of 8 Pages


SCHEDULE 13D
 
CUSIP No.   37244C101      
  
Page   2   of   8  Pages

1
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Julian C. Baker
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
  o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
2,941,272
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
2,941,272
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,941,272
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.0%
14
TYPE OF REPORTING PERSON (See Instructions)
IN


Page 2 of 8 Pages

SCHEDULE 13D
 
CUSIP No.  37244C101      
  
Page   3   of   8    Pages

1
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Felix J. Baker
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x 
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
  o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
2,941,272
8
SHARED VOTING POWER
2,941,272
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
2,941,272
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,941,272
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.0%
14
TYPE OF REPORTING PERSON (See Instructions)
IN


Page 3 of 8 Pages



Item 1. Security and Issuer.
 
This statement on Schedule 13D relates to the common stock, $0.0001 par value (the “Common Stock”), of Genomic Health, Inc. a Delaware corporation (the “Company”), whose principal executive offices are located at 301 Penobscot Drive, Redwood City, California 94063.
 
Item 2. Identity and Background.
 
This statement is being filed by Julian C. Baker and Felix J. Baker (each, a “Reporting Person”), each of whom is a United States citizen. Set forth below is certain information with respect to each Reporting Person:
 
Name
Business Address
Present Principal Occupation
Julian C. Baker
667 Madison Avenue
New York, NY 10021
Managing Member, Baker Bros. Advisors, LLC (an entity engaged in investment activities)
Felix J. Baker
667 Madison Avenue
New York, NY 10021
Managing Member, Baker Bros. Advisors, LLC (an entity engaged in investment activities)

During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in his being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violations with respect to such laws.
 
Item 3. Source and Amount of Funds or Other Consideration.
 
The funds used to purchase the shares of Common Stock reported in Item 5 below were provided from the available working capital of the entities there indicated.
 
Item 4. Purpose of Transaction.
 
The entities referred to in Item 5 below acquired the shares of Common Stock set forth therein solely for investment. The Reporting Persons expect to review from time to time the investment positions of these entities and may, depending on market and other conditions, increase or decrease their holdings.
 
Whether the entities purchase any additional shares of Common Stock or dispose of any shares of Common Stock, and the amount and timing of any such transactions, will depend upon the Reporting Persons’ continuing assessments of pertinent factors, including the availability of shares of Common Stock for purchase at particular price levels, the Company’s business and prospects, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the Board of Directors and management of the Company, the availability and nature of opportunities to dispose of shares in the Company and other plans and requirements of the particular entities. Depending upon their assessments of these factors from time to time, the Reporting Persons may change their present intentions as stated above, including determining to acquire additional shares of Common Stock (by means of open market or privately negotiated purchases) or to dispose of some or all of the shares of Common Stock under their control. The Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Company or any sale of its assets or any change in its Board of Directors, management, capitalization, dividend strategy, charter or by-laws, or any other change in its business or corporate structure or with respect to the delisting or deregistration of any of its securities including, without limitation, those matters described in subparagraphs (a) though (j) of Item 4 of Schedule 13D.
 

Page 4 of 8 Pages


 
Julian C. Baker is a Director of the Company.
 
Item 5. Interest in Securities of the Issuer.
 
Set forth below is the aggregate number of shares of Common Stock held as of the date hereof by each of the following, together with the percentage of outstanding shares of Common Stock that such number represents based upon 24,529,214 shares outstanding, as reported on the Company’s SEC Form 10Q filed on November 14, 2006.
 

       
Percent of class
  
 Name
  
 Number of Shares
  
Outstanding
  
Baker Bros. Investments, L.P.
    
173,897
    
0.7
%
Baker Bros. Investments II, L.P.
    
16,444
    
0.1
%
Baker Biotech Fund I, L.P.
    
606,709
    
2.4
%
Baker Brothers Life Sciences, L.P.
    
1,738,099
    
7.1
%
14159, L.P.
    
38,467
    
0.2
%
Baker/Tisch Investments, L.P.
    
193,759
    
0.8
%
FBB Associates
    
173,897
    
0.7
%
Total
    
2,941,272
    
12.0
%
 
By virtue of their ownership of entities that have the power to control the investment decisions of the limited partnerships listed in the table above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power to vote or direct the vote of and shared power to dispose or direct the disposition of such securities. Julian C. Baker and Felix J. Baker are also the sole partners of FBB Associates, a general partnership, and as such may be deemed to be beneficial owners of shares owned by FBB Associates and may be deemed to have shared power to vote or direct the vote and dispose or direct the disposition of those shares.
 
The following transactions in Common Stock were effected by the entities noted below during the nineteen days preceding the filing of this statement. The transactions in common stock effected the twentieth to sixtieth days are disclosed on the previous Schedule 13D filed on February 22, 2007. All transactions were effected in the over-the-counter market directly with a broker-dealer. None of the reporting Persons has effected any other transactions in Common Stock during this period.
 

Page 5 of 8 Pages



 
Name
Date
Number of Shares
Transaction
Price/ Share
14159, L.P.
3/1/2007
1,123
Purchase
18.2041
Baker Bros. Investments II, L.P.
3/1/2007
78
Purchase
18.2041
Baker Biotech Fund I, L.P.
3/1/2007
13,004
Purchase
18.2041
Baker Brothers Life Sciences, L.P.
3/1/2007
35,170
Purchase
18.2041
Baker/ Tisch Investments, L.P.
3/1/2007
725
Purchase
18.2041
14159, L.P.
3/1/2007
8
Purchase
17.9
Baker Biotech Fund I, L.P.
3/1/2007
80
Purchase
17.9
Baker Brothers Life Sciences, L.P.
3/1/2007
216
Purchase
17.9
Baker/ Tisch Investments, L.P.
3/1/2007
4
Purchase
17.9
14159, L.P.
3/1/2007
335
Purchase
17.77
Baker Bros. Investments II, L.P.
3/1/2007
24
Purchase
17.77
Baker Biotech Fund I, L.P.
3/1/2007
3,899
Purchase
17.77
Baker Brothers Life Sciences, L.P.
3/1/2007
10,543
Purchase
17.77
Baker/ Tisch Investments, L.P.
3/1/2007
199
Purchase
17.77
14159, L.P.
3/2/2007
241
Purchase
18.0242
Baker Bros. Investments II, L.P.
3/2/2007
17
Purchase
18.0242
Baker Biotech Fund I, L.P.
3/2/2007
2,812
Purchase
18.0242
Baker Brothers Life Sciences, L.P.
3/2/2007
7,604
Purchase
18.0242
Baker/ Tisch Investments, L.P.
3/2/2007
144
Purchase
18.0242
14159, L.P.
3/9/2007
1
Purchase
18.4400
Baker Biotech Fund I, L.P.
3/9/2007
4
Purchase
18.4400
Baker Brothers Life Sciences, L.P.
3/9/2007
12
Purchase
18.4400
14159, L.P.
3/9/2007
5,374
Purchase
18.2809
Baker Bros. Investments II, L.P.
3/9/2007
376
Purchase
18.2809
Baker Biotech Fund I, L.P.
3/9/2007
62,321
Purchase
18.2809
Baker Brothers Life Sciences, L.P.
3/9/2007
168,548
Purchase
18.2809
Baker/ Tisch Investments, L.P.
3/9/2007
3,181
Purchase
18.2809

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
 
Except as reported herein, neither of the Reporting Persons has any express contracts, arrangements or understandings with any other Reporting Person with respect to the securities of the Company. Except as set forth in Item 7 below, none of the Reporting Persons has any contracts, arrangements, understandings or relationships with the Company.
 
Item 7. Material to Be Filed as Exhibits.
 
Exhibit 1. Agreement regarding the joint filing of this statement.
 
 
Page 6 of 8 Pages

 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
March 13, 2007

 
By:
 /s/ Julian C. Baker
   
Julian C. Baker
     
 
By:
 /s/ Felix J. Baker
   
Felix J. Baker


Page 7 of 8 Pages

EXHIBIT 1

AGREEMENT
 
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
 
March 13, 2007

 
By:
 /s/ Julian C. Baker
 
  
Julian C. Baker
     
 
By:
 /s/ Felix J. Baker
 
  
Felix J. Baker

Page 8 of 8 Pages
 -----END PRIVACY-ENHANCED MESSAGE-----